TY - JOUR
T1 - Progress in cytochrome P450 active site modeling
AU - Kemp, Carol A.
AU - Maréchal, Jean Didier
AU - Sutcliffe, Michael J.
N1 - Funding Information:
The authors express their thanks to Gordon Roberts, Roland Wolf, Mark Paine, and Stewart Kirton for stimulating discussions. The authors are also grateful for funding from a Drug Metabolism Consortium comprising 12 companies: AstraZeneca, Aventis, Boehringer-Ingelheim, Celltech Chiroscience, GlaxoSmithKline, Hoffmann-La Roche, Janssen Pharmaceutica, Merck Sharp and Dohme, Novartis, Novo Nordisk, Pfizer, and Wyeth.
PY - 2005/1/15
Y1 - 2005/1/15
N2 - Models capable of predicting the possible involvement of cytochromes P450 in the metabolism of drugs or drug candidates are important tools in drug discovery and development. Ideally, functional information would be obtained from crystal structures of all the cytochromes P450 of interest. Initially, only crystal structures of distantly related bacterial cytochromes P450 were available-comparative modeling techniques were used to bridge the gap and produce structural models of human cytochromes P450, and thereby obtain some useful functional information. A significant step forward in the reliability of these models came four years ago with the first crystal structure of a mammalian cytochrome P450, rabbit CYP2C5, followed by the structures of two human enzymes, CYP2C8 and CYP2C9, and a second rabbit enzyme, CYP2B4. The evolution of a CYP2D6 model, leading to the validation of the model as an in silico tool for predicting binding and metabolism, is presented as a case study.
AB - Models capable of predicting the possible involvement of cytochromes P450 in the metabolism of drugs or drug candidates are important tools in drug discovery and development. Ideally, functional information would be obtained from crystal structures of all the cytochromes P450 of interest. Initially, only crystal structures of distantly related bacterial cytochromes P450 were available-comparative modeling techniques were used to bridge the gap and produce structural models of human cytochromes P450, and thereby obtain some useful functional information. A significant step forward in the reliability of these models came four years ago with the first crystal structure of a mammalian cytochrome P450, rabbit CYP2C5, followed by the structures of two human enzymes, CYP2C8 and CYP2C9, and a second rabbit enzyme, CYP2B4. The evolution of a CYP2D6 model, leading to the validation of the model as an in silico tool for predicting binding and metabolism, is presented as a case study.
KW - Cytochromes P450
KW - Drug binding
KW - Drug discovery
KW - Drug metabolism
KW - Predictive tools
KW - Structural models
UR - http://www.scopus.com/inward/record.url?scp=9944259598&partnerID=8YFLogxK
U2 - 10.1016/j.abb.2004.08.026
DO - 10.1016/j.abb.2004.08.026
M3 - Article
AN - SCOPUS:9944259598
SN - 0003-9861
VL - 433
SP - 361
EP - 368
JO - Archives of biochemistry and biophysics
JF - Archives of biochemistry and biophysics
IS - 2
ER -